Organization | Halozyme Therapeutics

Halozyme Therapeutics Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: San Diego CA United States (1998)

Organization Overview

First Clinical Trial

2005

NCT00311519

First Marketed Drug

2005

hyaluronidase (bovine) (Wydase)

First NDA Approval

2005

hyaluronidase (human recombinant) (Hylenex)

Last Known Activity

2019

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Halozyme and BiolineRx Ltd | HALOZYME THERAP | Halozyme Therapeutics

Active Ingredients

Marketed Drugs (2)

hyaluronidase (bovine) (Wydase) (2005)

hyaluronidase (human recombinant) (Hylenex) (2005 NDA)

Drugs in Phase 4 Trials (6)

Key: Halozyme Therapeutics (5) Acquired (1)

hyaluronic acid (1 trial)

hyaluronidase (human recombinant) (Hylenex) (33 trials)

insulin glulisine (Apidra) (4 trials)

insulin lispro (humalog) (11 trials)

ringer's lactate (1 trial)

testosterone (delatestryl) (6 trials)

Drugs in Phase 3 Trials (3)

Key: Halozyme Therapeutics (2) Acquired (1)

gemcitabine (gemzar) (6 trials)

oxybutynin (ditropan) (1 trial)

paclitaxel (taxol) (5 trials)

Drugs in Phase 2 Trials (18)

Key: Halozyme Therapeutics (16) Acquired (2)

atezolizumab (Tecentriq) (3 trials)

C1 Esterase Inhibitor (Human) (Cinryze) (2 trials)

cobimetinib (cotellic) (1 trial)

eribulin (halaven) (1 trial)

fluorouracil (efudex) (2 trials)

insulin glargine (toujeo) (3 trials)

insulin human (humulin) (5 trials)

irinotecan (Camptosar) (1 trial)

leucovorin (2 trials)

linagliptin (tradjenta) (1 trial)

mitomycin (mutamycin) (2 trials)

Motixafortide (1 trial)

naltrexone (revia) (2 trials)

oxaliplatin (eloxatin) (2 trials)

pegph20 (11 trials)

pembrolizumab (keytruda) (1 trial)

ramucirumab (cyramza) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (6)

Key: Halozyme Therapeutics (5) Acquired (1)

abiraterone (zytiga) (1 trial)

bococizumab (1 trial)

ceftriaxone (rocephin) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

ondansetron (zofran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Angioedema (Phase 2)

Angioedemas, Hereditary (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma, Ductal (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Pancreatic Ductal (Phase 3)

Cholangiocarcinoma (Phase 1)

Dehydration (Phase 4)

Dermatitis (Phase 2)

Dermatitis, Allergic Contact (Phase 2)

Dermatitis, Contact (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 2)

Emergencies (Phase 4)

Esophageal Neoplasms (Phase 2)

Hypercholesterolemia (Phase 1)

Lung Neoplasms (Phase 1)

Neoplasms (Phase 1)

Osteoporosis (Phase 1)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 57
# of Trial APIs: 33